Importantly, many of these altered pathways are consistent with the mutational signatures shared between T-LUAD and T-SCLC (e.g., mutations in PI3K/AKT, WNT and epigenetic regulators) [55], suggesting these mutations may prime tumors for SCLC transformation. This evidence concerns the gene AKT1 and small cell lung carcinoma.